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ABSTRACT
Background: Mastocytosis is a rare disorder
with diverse clinical manifestations. In
cutaneous mastocytosis the mast cell
infiltration is limited to the skin, but is often
associated with systemic symptoms due to the
release of mast cell mediators.
Case Report: We report a 6-month-old male
infant who had skin lesions of various
morphologies (macules, papules, plaques, and
nodules) and sizes, persistent blistering and
frequent flushing episodes for half a year. Vital
signs and physical examinations were
unremarkable. No abnormalities in the
laboratory tests were found except for a serum
tryptase level (STL) of 11.8 ng/ml. The
histological and immunohistochemical
examinations confirmed the diagnosis of
cutaneous mastocytosis. The patient was first
treated with methylprednisolone, oral
levocetirizine, and topical fusidic
acid/betamethasone cream. Subsequently the
treatment was tapered and stopped within
9 weeks. The child’s symptoms improved and
were successfully controlled with intermittent
courses of ketotifen and topical hydrocortisone
over 3 years.
Conclusion: Childhood cutaneous
mastocytosis usually has a favorable prognosis,
but in some cases the disease can progress with
skin manifestations necessitating a more active
systemic and topical treatment.
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INTRODUCTION
Mastocytosis comprises a heterogeneous
spectrum of diseases characterized by a range
of local and systemic symptoms. The current
World Health Organization (WHO)
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classification, updated in 2008, differentiates
one exclusively cutaneous form from the
systemic forms of mastocytosis [1–3].
Cutaneous mastocytosis (CM) is a condition
classified according to clinical symptoms and
identified by an abnormal accumulation of
mast cells limited to the skin. Clinically, CM is
divided into three main variants:
maculopapular CM (or urticaria pigmentosa),
characterized by disseminated small patches,
papules, and plaques; diffuse CM, affecting
large areas of the skin with yellow-red
erythroderma-like, diffuse doughy-firm
swellings and solitary mastocytoma, partly
characterized by blistering and found
predominantly in children. The much rarer
forms are defined as the plaque form, the
nodular form, and telangiectasia macularis
eruptiva perstans. These disorders do not
represent independent variants in the WHO
classification and are assigned to maculopapular
CM [1–4].
CM has been diagnosed in patients with
disseminated bullous lesions, plaques, nodules,
and other clinical presentations such as
localized mastocytosis, solitary and multiple
mastocytomas, and some other unusual
morphologies [4, 5].
We present a 3-year-long follow-up of a child
with skin lesions of various morphologies and
sizes, continuous blistering, and frequent
flushing during the first 6 months of his life.
Successful treatment was achieved with a short
methylprednisolone course and subsequent
intermittent H1 receptor antagonist and
topical treatments.
CASE REPORT
A 6-month-old male infant was referred with
different types of skin lesions, persistent
blistering, and frequent spontaneous flushing
since birth. The child did not have any physical
or psychomotor disturbances. No significant
family or antenatal history data existed.
Intermittent courses with oral H1 blockers and
topical antibiotics and corticosteroids had been
administered without improvement.
On admission, vital signs and chest and
abdomen examinations were unremarkable,
while hepatosplenomegaly and
lymphadenopathy were absent. A variety of
skin lesions (reddish-brown, partially with
peau d’orange appearance, macules, papules,
plaques, and nodules), sized 4–65 mm, were
distributed on the neck, trunk, buttocks, and
extremities. Tense bullae, erosions, and crusts
were revealed to overlay plaque surfaces (Figs. 1,
2a). Darier’s sign was demonstrated (Fig. 2b).
Oral mucosa was not affected. Within the first
2 days, we observed several flushing episodes,
unprovoked by any triggering factors.
Laboratory findings did not disclose
hematologic, biochemical, or liver function
abnormalities. Serum tryptase level (STL) was
11.8 ng/ml (reference range \11.4 ng/ml). A
biopsy taken from an elevated plaque with
vesiculation revealed melanin in the
basal/suprabasal layer, subepidermal bulla,
Fig. 1 One of the multiple reddish-brown plaques with
peau d’orange appearance
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dense mast cell infiltration, and some
eosinophils in the dermis (Fig. 3a).
Immunohistochemical staining for CD117
antibody was positive (Fig. 3b). Toluidine blue
and Giemsa stainings showed metachromatic
granules in the cytoplasm of the infiltrating
cells (Fig. 4a, b). The pediatric consultation did
not reveal systemic symptoms.
The patient was initially treated with
methylprednisolone 0.6 mg/kg once daily (o.d.)
intramuscularly (3 days), oral levocetirizine
1.25 mg o.d, 2% topical fusidic acid, and 0.1%
betamethasone valerate cream. Subsequently, the
dose of methylprednisolone was tapered, given
orally (0.5 mg/kg o.d [4 days], 0.5 mg/kg every
other day [2 weeks], 0.5 mg/kg twice a week
[2 weeks]) and stopped. After 10 days,
levocetirizine was replaced with ketotifen
0.05 mg/kg twice daily for eight more weeks and
the cream was replaced with 1% hydrocortisone
cream for amonth. The child was closely followed
up during the treatment. His symptoms improved
remarkably. There were no adverse effects of the
therapy. Over the following 3 years, the clinical
manifestations were successfully managed with
intermittent ketotifen and topical hydrocortisone
Fig. 2 a Nodular lesion on the neck, b Darier’s sign
Fig. 3 a Subepidermal bulla and dermal inﬁltration
(H&E; 9200), b CD117-positive mast cell inﬁltration
(9400)
Fig. 4 a Toluidine blue (9200) and b Giemsa (9400)
staining of mast cell dermal inﬁltration
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treatments. Parents were counseled on the
avoidance of triggering factors for mediator
release. At the last follow-up (3.5 years of age),
only a few pale-brownish macules were seen with
no blistering or isolated flushing episodes. The STL
declined to 7.2 ng/ml. For 3 years the patient did
not show any symptoms consistent with systemic
mastocytosis.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from the
parent for the child being included in the study
and for the publication of the patient
photographs.
DISCUSSION
The diversity of CM skin manifestations is
evident when reviewing the literature. With
regard to cutaneous lesions, our case seems to
belong to the maculopapular and nodular CM,
showing a range of lesions of various sizes and
morphologies. Such varied lesions are
encountered more often in pediatric than in
adult CM where a more uniform presentation of
small patches and papules is common [1–5].
The bullous form of mastocytosis is a rare,
morbid condition typically encountered in
young children [2]. Episodic blistering has
been reported in maculopapular CM, which
usually occurs after stroking or rubbing of the
lesional skin and rarely appears spontaneously
[4]. There are also reports of nodular forms with
occasional blistering as well as predominant
bullous variants of CM. In fact, the long-living
bullous manifestations are characteristic of the
diffuse CM [3–5]. It is interesting that in our
case, the varied skin lesions, not corresponding
to diffuse CM, were associated with an
uninterrupted bulla formation for half a year
and no improvement with H1 receptor blockers
or topical corticosteroids/antibiotics.
In our case, the flushing episodes were very
frequent, spontaneous, and not induced by any
precipitating factor (ambient temperature, food,
exercise, stress, medication, etc.). This was the
only systemic clinical symptom. No other signs
of internal organ involvement were revealed
except for an STL of 11.8 ng/ml. This is not
indicative of systemic mastocytosis, where the
STL reference value is[20 ng/ml. This slightly
elevated STL might relate to flushing as a single
symptom of the mast cell mediator release. It is
observed more often in patients with systemic
involvement, but may also occur in those with
purely cutaneous manifestations [1–6].
In our case, the diagnosis of CM was made
based on clinical manifestations, Darier’s sign,
and histopathological and immunohistochemical
findings (anti-c-kit/CD117 with a high specificity
and sensitivity for mast cells). It is widely
accepted that growth and differentiation and
proliferation of mast cells are controlled by the
tyrosine kinase receptor c-Kit (CD117) and its
ligand stem cell factor. It is also controlled by
other cytokines such as IL-4, IL-6, IL-10, and IL-13
[1, 2]. Recent genetic studies have identified new
proteins (Lin28b) that are of interest in mast cell
disease [7].
Adequate management during the early
phase of CM in children may prevent
potential complications. Counseling of
patients/parents is important to avoid
mediator release precipitating factors and treat
mast cell mediator release symptoms. CM
remissions have been reported following
treatments with anti-mediator drugs such as
H1 and H2 receptor antagonists and cromolyn
sodium (oral and topical). Topical/intralesional
corticosteroids, phototherapy, and topical
calcineurin inhibitors may be useful [8–10].
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In our case, considering the previous therapy
failure, we applied a short course of
methylprednisolone, combined with an H1
receptor blocker (levocetirizine) and topical
mid-potency corticosteroid. This was followed
by intermittent H1 receptor blocker (ketotifen)
and topical hydrocortisone courses. This
treatment reduced the patient’s persistent
blistering and the frequency of flushing
episodes. No adverse events occurred. The
3-year-long follow-up demonstrated that our
approach to a refractory, though not severe,
clinical form of CM can be to the patient’s
benefit. Of note, neither low-dose H2 receptor
blockers (for pediatric use) nor sodium
cromoglycate are available in Bulgaria.
The debate between more or less aggressive
management options for pediatric CM
continues. Systemic and topical corticosteroids
have demonstrated good therapeutic results in
some cases of bullous mastocytosis, as reported
in the literature [11, 12].
CONCLUSION
Childhood CM usually has a benign course and
most of the cases resolve by puberty [2, 3]. With
proper treatment and family education on
avoiding triggering factors, gradual resolution
of both skin lesions and mast cell-mediated
symptoms may be observed. Despite the lack of
systemic involvement, some patients with CM
may develop skin manifestations that are
difficult to control. Therefore, follow-up with
rigorous evaluation and relevant management
is required for each individual case.
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